XOMA Share Price

Open 6.92 Change Price %
High 7.05 1 Day 0.06 0.89
Low 6.63 1 Week 0.46 7.23
Close 6.82 1 Month 0.08 1.19
Volume 120089 1 Year 6.30 1211.54
52 Week High 8.13
52 Week Low 0.34
XOMA Important Levels
Resistance 2 7.21
Resistance 1 7.05
Pivot 6.83
Support 1 6.59
Support 2 6.43
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

XOMA Corporation (NASDAQ: XOMA)

XOMA Technical Analysis 4
As on 23rd Jun 2017 XOMA Share Price closed @ 6.82 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.44 & Buy for SHORT-TERM with Stoploss of 6.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
XOMA Target for June
1st Target up-side 7.12
2nd Target up-side 7.57
3rd Target up-side 8.03
1st Target down-side 5.82
2nd Target down-side 5.37
3rd Target down-side 4.91
XOMA Other Details
Segment EQ
Market Capital 188892816.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.xoma.com
XOMA Address
XOMA
2910 Seventh Street
Berkeley, CA 94710
United States
Phone: 510-204-7200
XOMA Latest News
XOMA Corporation (XOMA) Getting Negative Press Coverage, Analysis Finds   The Cerbat Gem   - 23rd Jun 17
XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets ...   GlobeNewswire (press release)   - 18th May 17
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of ...   GlobeNewswire (press release)   - 24th Apr 17
XOMA Corporation (NASDAQ:XOMA) Is A Changed Company: Here's How And Why   Insider Financial   - 20th Apr 17
XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program   GlobeNewswire (press release)   - 18th Apr 17
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program ...   GlobeNewswire (press release)   - 28th Mar 17
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt ...   GlobeNewswire (press release)   - 22nd Mar 17
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from ...   GlobeNewswire (press release)   - 22nd Dec 16
XOMA Announces Reverse Stock Split   GlobeNewswire (press release)   - 15th Oct 16
Buy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital ...   Seeking Alpha   - 25th Jul 16
Interactive Technical Analysis Chart XOMA Corporation ( XOMA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on XOMA Corporation
XOMA Business Profile
XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.